Trial Profile
An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Registrational
- Acronyms TREMENDOUS
- Sponsors AstraZeneca
- 15 Dec 2023 Planned number of patients changed from 300 to 210.
- 14 Mar 2023 Status changed from not yet recruiting to recruiting.
- 21 Jan 2023 Trial design presented at the 2023 Gastrointestinal Cancers Symposium.